Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProStrakan Group, a specialty pharmaceutical company, has signed two exclusive license and supply agreements for certain countries in the pacific region and for Turkey for Sancuso, the company's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting in patients receiving chemotherapy for up to five consecutive days.
Subscribe to our email newsletter
Singapore-based Invida Pharmaceutical Holdings will market Sancuso in Australia, Indonesia, the Philippines, Thailand and Vietnam, while Dubai-based NewBridge Pharmaceuticals will market Sancuso in Turkey. ProStrakan has already partnered with NewBridge for the marketing of Sancuso in the Middle East and Africa.
Under the terms of the agreements, ProStrakan will receive undisclosed upfront and milestone payments, subject to the achievement of certain approvals and sales targets. Invida and NewBridge will be required to purchase Sancuso directly from ProStrakan at a pre-agreed price.
Sancuso is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, steadily into the bloodstream for up to seven days. Sancuso has been shown to be as efficacious as oral granisetron in preventing the side effects of nausea and vomiting in patients undergoing chemotherapy, the company said.
Wilson Totten, ProStrakan’s CEO said: With US approval for Sancuso achieved, this product has caught the attention of pharmaceutical companies globally, validating our strategy of outlicensing it in territories that are non-core for ProStrakan. We have now constructed a significant potential ongoing revenue stream from Sancuso.